Navigation Links
Advanced Market Research for Medical Device Manufacturers
Date:3/3/2011

DENVER, March 3, 2011 /PRNewswire-USNewswire/ -- AORN Works, a subsidiary of the Association of periOperative Registered Nurses (AORN), announced that its market research and surgical insights division will lead the strategic priorities of its business.

(Logo: http://photos.prnewswire.com/prnh/20101001/DC75398LOGO)

On behalf of clients, market research/surgical insights measure the attitudes of perioperative professionals who are the end users of medical products and services. The new strategy results from its niche ability to provide exceptional market intelligence to medical device manufacturers and service providers that sell to operating rooms throughout the United States.  

In addition to its market research division, AORN Works specializes in executive level interim and permanent placement services for perioperative departments.

"As a subsidiary of AORN, we have contact with more than 40,000 operating room professionals who we can use as a resource for our market research," said Vicki Faas, general manager for AORN Works.  "Through our opt- in market research database, we are also able to tap into a broad network of perioperative team members including OR nurses, management, scrub and central sterile technicians, surgeons and anesthesiologists."

AORN Works conducts research that translates into actionable information to expedite the development of products and services that benefit surgical patients in the ambulatory surgery and hospital settings.  Capabilities include market needs assessments, target market analysis, voice of the customer, product testing, strategic advisory boards, marketing communications development and testing, customer satisfaction and forecasting.

About AORN Works

Headquartered in Denver, Colo., AORN Works is a subsidiary of the Association of periOperative Registered Nurses (AORN), the nation's largest perioperative nursing association.  AORN Works' mission is to provide customers with expert resources and solutions grounded in AORN standards and recommended practices that will enhance safe patient care and support optimal outcomes in the perioperative setting.  Please visit www.AORNworks.org.


'/>"/>
SOURCE AORN Works
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... ... that adult use in states where cannabis is legal will generate ... $559 million will be from cannabis specific taxes, such as ... remaining $96 million will be earned from state sales taxes that ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... can quickly sideline athletes. A type of groin injury, it occurs when the ... to serious, intense pain in and around the lower torso, as well as ...
(Date:3/27/2017)... NY (PRWEB) , ... March 27, 2017 , ... ... in epigenetic research products enables researchers to pursue the recent RNA methylation “gold ... methylation . In light of the newfound characteristics of N6-methyladenosine, or m6A ...
Breaking Medicine News(10 mins):